Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
loooking like a good bottom
AI stocks on fire
good QUBT fortunes to you sir
yeah ok TOMDF shill
burner phones, fake IP’s and multiple email addy’s
all written in your very own “JoeyForkitBolo” Reddit post…
that says it all chump…!
I don’t believe 1 word you say…
MOO disgusting
no one misunderstood anything Warp
er - I mean “Joey” lol
cause it’s all lies - just like your TOMDF pumping and touting
congrats - your a real piece of work pal
MOO dolt
ah quit your lying …
you were counting your worthless TOMDF shares - right …?
and framing a few certificates to hang on the old bathroom wall - eh Redspudda
but hey maybe Gerald can come work for you now - now that TOMDF is dissolved
you know - spinning them Greesemonkey ratchets
you rock Redsie - sure glad I followed you and the Boiler Room Pump Boys to TOMDF
how many lemmings did you suck into Geralds scam to lose their hard earned money…?
Redsputta - reputation permanently shottada…!
MOO shill
sorry to say Mista Redspudda
you and the pathetic JFB faithful lap dawg won't be posting any more Share Structure updates now - will you pal...?
just CLICKIE here brah:
https://todosmedical.com/about
oh, erh - a wait a second - Dah - that link is broke - Gheesh - you're so right Redskie its "BROKE" sport...
***** BANKRUPT - INSOLVENT - LIQUIDATED - DISSOLVED - TERMINATED *****
now why would that be Mista Redspudda - could it have anything to do with this - ya think...?
Todos Medical Announces Insolvency Proceedings in Israel
December 22, 2023
https://finance.yahoo.com/news/todos-medical-announces-insolvency-proceedings-222800017.html
but hey - here's to you and your Boiler Room ilk Mista Redspudda:
MOO hilarious
for the guy that said Jonathan Najarian has a huge social media following
that look on Jonathan's face says it all - eh Mr Redsputter...?
and you gotta love Geralds "DEFENSIVE" posturing - looks like a deer in the head lights:
keep buying that Tollovid fake Chinese gromwell root - if you still can Sport...!
https://www.amazon.com/tollovid/s?k=tollovid
it may just cure you of the lastest Gerald Deranged Syndrome pal - lolzzz:
poor Stewart Varney - that look of 'TOTAL DISGUST' on his says it all folks:
and in case amnesia hasn't already conveniently set in...
try wrapping your 'brain cells' around this one Honey:
https://investor.todosmedical.com/
where did all $138-Mil. go in 5 years time pal...?
Investigate Gerald Commissiong
investigate the TOMDF Boiler Room Pump Boy shills, touts and dolts
SMH - reality is always stranger than fiction - with Redsputter and his ilk...!
MOO hooie
here's some real "DERANGED SYNDROM" for ya Joey
SHM - we got a real "winner" here with JoeyForkitBolo folks
Better Than Remdesivir - my royal right cheek arse...
Pfizer is banging down Todos Medical's front door to buy Tollovid from Gerald - ha..!
hows those TolloUp Buttercup sales doing - eh Joey...?
MOO Dooki in TOMDF bam-bam
MOO dolt
Gerald Commission is a chronic habitual BLAMER of OTHERS
for his own shortcomings, failures, complete & utter incompetencies, and highly suspect CEO fiduciary responsibilities
all as a twice failed flunky CEO & Stanford University "FINANCIAL ENGINEER" hack
IMHO, he is nothing more than a tool, shill and REPEAT SCAM ARTIST
working with/for the Astoria Queens toxic death spiral finance mafia boys
TOMDF and AMBS have shown a concerted & orchestrated effort to have its pps manipulated
you know - by the TOMDF BOILER ROOM PUMP BOYS - and we know well who you all are ...
Redsputter, JoeyForkitBolo, Mauibound, Greaseman, Gman111, theswordman, Sloan, etc etc etc ...!
Tel Aviv, Israel is one of the world's largest off-shore havens for all kinds of OTC scams
where liquid assets get moved around like playdough - and disappear into thin air
with TOMDF being OTC non-compliant limited-reporting for a few years now
there's no telling when in hell (+/-) $138-Mil. went in 5 years total time
these are simply eye popping ginormous salaries for when TOMDF was actually issuing filings
just what in hell did these TOMDF employees do to earn this size bootie - all at SH's expense...?
SMH - TOMDF's reality is stranger than Screwy in St Loui ...!
and there's a good reason why there's so much confusion...!
Figgies got Gerald Commissiong down pat...!
MOO outrageous
wowza and to think the TOMDF SH's paid this buttwipe CEO $720k/yr salary for this...?
plus benefits package, retirement, medical, car, travel, speaking engagements, hotels, diners, etc etc etc
and this is what you fine folks get in return...?
and this is a Stanford University "Financial Engineer" graduate...?
good luck with this CEO hack and scam artist sport...!
better than Remdesivir my royal arse...
MOO dunce
yo theswordman, erh I mean Redsputter - wink wink
the only thing unwitting round here is you
and the stream of BS and chaos that follow you around - like bad Karma
just like the PUMP jobs you did on TOMDaFk and VERB
you and your multiple alias, burner phone, fake IP address boiler room pump boys and nothing more than:
you can't hold a match to me sport - all you can do is spin...!
SMH - nothing to see here folks with Redspudder
MOO putz
BAF MONI...!
MOO pathetic
yo Redsputter, erh I mean Swordie...wink wink
Chris Cuomo has zero interest in Tolloup, Buttercup, or Giddyup for that matter
none - nada - nill ...!
but you keep 'BOILER ROOM PUMPIN' the false narratives that he does
just like you always do - with everything TOMDF...!
can you spell insolvent and dissolvement...?
SMH - can't make this stuff up folks
MOO pathetic
no I honestly don’t have that problem
but it seems like territory that you’re fairly familiar with - eh Swordie…?
projection is perception
hasta leugo amigo
resident expert - what...???
seems like we got a lot-o-those expert type folks around here
so many so - that TOMDF is in insolvency and liquidation proceedings - Whoa imagine that - lookie here:
https://finance.yahoo.com/news/todos-medical-announces-insolvency-proceedings-222800017.html
looks like AMZN took 4 + days to showcase Tolloup Buttercup Chinese gromwell root extract again for sale
its obvious you checked the accuracy of my post #19739 at the time and saw this shite product was not available then...!
only took you 4+ days to see that it had changed and are now calling me me a liar
when in fact, the Tolloturd product was not in stock or advertised on their web portal
but here - let me help you with your dishonesty thinking because I now how painful it is to be proven wrong
just like your choice to believe in this shyster CEO and poor your money into his pockets for years
here's were the real LIES and BULLSHIT rubber meets the road pal:
hows that Anti-COVID Pill BULLSHIT national media coverage doing - eh Redspudder I mean theSwordman...?
how did all these BULLSHIT TOMDF STAGED & FAKE events ever workout for you - eh Swordie...?
01. playing/sponsoring 'flag-football' is good for shareholders
02. issuing free shares to Wall St. 'has-beens' will attract new investors
03. hiring an 'x-body builder' for PR is a wise decision
04. hiring a 'kiddie influencer' is a sound decision
05. hiring a TaiBo instructor for Todos promotions is going to reverse serial dilution
06. holding photo op's w/ Michael Irvin and NYSE backdrop is good marketing strategy
07. selling 'gummy bears' is the way of the future
08. selling 'no-name' high priced vending machine products is smart
09. has 10-Bil. AS avalanche over-hang on the heads of shareholders is smart
10. has 3-Bil. In OS folks, yes that 3-BILLION shares issued folks
11. now OTC Compliant and is non-reporting
12. thinks serial diluting the shit out of existing shareholders monthly is "financial engineering"
13. issues fake "Word Salad" tweets & PR's repeatedly and non-stop
14. $5-Mil. qtrly. losses on the books and growing
15. desperate crowdfunding offering which won’t raise diddly
16. promotes Israel & Greece EAU’s - but never gets it done
17. keep saying major news is coming - but somehow it never does
18. only issue conference news like JPM and the pps goes down – mostly on ‘sell the news’ dilution
19. CEO spends all day on Twitter arguing with MD & PhD’s thinking it’s a smart idea
20. investing in failed Para Moto CV-19 mobile test labs amounting to dire financial losses
21. $50-Mil. vending machine business unable to launch due to "cash flow" shortages per CEO
22. crowdfunding financial assistance way behind with missed launch schedules & dates
23. fake spokesperson RS answering MB posts on behalf of company with ulterior motives
24. GC spends all day on Twitter - shareholders quote him thinking GC’s statements are the truth
25. the deal to sell 3-CL expired Dec 31st w/Dr. Orad - still nothing except CEO on Twitter rant
26. Provista employees snot paid, complaining on public forums – GC didn’t want to meet w/them
27. Monkey Pox test kits only made it to a public GA grammar school – where’s distribution of kits
28. Pres. Biden ends COVID Pandemic on 01/30/23 – Tollovid sales will drop bigley
29. CEO trying desperately to jump on LH-COVID wagon, but that’s a risk, as in all eggs in 1 basket
30. Lympro…? oh yeah - waiting for the ‘German’ polices list of approval before releasing the results
31. Videssa commercialized in 2023? yeah right – no Tollovid LH COVID data is very disturbing
32. just how many Tollovid bottles have been sold - when - what’s the total ROI – seems sketchy
33. just what’s happening with the purchase of the ultra-expensive Texas facility
34. Tollovid sales that have never materialized
35. monkeypox testing that’s brought in next to zero revenue
36. crowdfunding campaign that turned out to be a complete dud
37. 3CL Todos in China - GC said they’re sending samples - where exactly did they send them?
38. has 1:500 SH approved RS in filings just waiting for the right time to ‘drop the bomb’
39. Uplist in 2nd half of 2021 | we’re focused on creating SH value for our SH’s – my arse
40. TOMDF plans to launch Vedessa clinical study in 2022 in order to drive sales by 2023 my arse
41. CEO says NasDaq Uplisting 1st half of 2022, NCL Pharma acquisition of track – my arse
42. “As a result, we have our hospitalized COVID Program on pause" - say bye-bye to any EAU folks
43. Tollovir is dead - website was down for a week - dilution is through the roof.
44. Crowdfunding non-existent, botanical CBD Gummy Bears have gone nowhere
45. Employees being laid off left and right, let alone being paid, incl. former Rami Zigdon CEO owed salary
46. TOMDF is now PINK Delinquent non-reporting
47. dilution toxic death spiral financing will keep all TOMDF SH’s broke, you’ll NEVER get your $ out
48. GC unable to close a deal with Arad and NCL for IP rights to all things Tollo
49. Todos will now own 100% of 3CL Pharma but only has distribution rights of Tollo products in NA
50. all that TOMDF SH’s now have is distribution rights
51. TOMDF Accumulated Deficits closing in on $138-Mil in losses, potentially higher
52. TOMDF files for Insolvency hearings in Israel, as Christmas present to TOMDF shareholders on 12/22/23
53. Giddy-up Tollo-up Buttercup pumper boy Redspeed disappears from plain sight on 12/31/23
how did all these +5 Yr. long BULLSHIT PR's help with your $0.00 TOMDF stock trade account Redspeed, erh - I mean Swordman...?
TOMDF Scam Exposed in PR Chronological Order:
Todos Medical Announces Insolvency Proceedings in Israel
Dec 22, 2023 5:28pm EST
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Sep 26, 2023 11:01am EDT
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Aug 30, 2023 8:19am EDT
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Mar. 28, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace
Mar. 27, 2023
Todos Medical Supports Long COVID Awareness Day
Mar. 15, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Mar. 13, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Feb. 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Dec. 06, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Nov. 29, 2022
Todos Medical to Attend World Antiviral Congress
Nov. 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Nov. 16, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Nov. 10, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Oct. 14, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Oct. 06, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
Sep. 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
Sep. 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
Sep. 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
Sep. 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
Sep. 15, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
Sep. 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
Sep. 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
Sep. 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
Sep. 09, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
Sep. 02, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
Aug. 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
Aug. 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Aug. 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Aug. 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Aug. 23, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Aug. 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
Aug. 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
Aug. 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
Aug. 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Aug. 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 08, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Aug. 05, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 03, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Aug. 01, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Jul. 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
Jul. 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID
Jul. 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Jun. 30, 2022
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Jun. 23, 2022
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Jun. 21, 2022
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Jun. 13, 2022
Todos Medical Reports Day 45 Update for Case Study #6
Jun. 10, 2022
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Jun. 07, 2022
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Jun. 03, 2022
Todos Medical Reports Day 26 Update For Case Study #4
Jun. 01, 2022
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 27, 2022
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 06, 2022
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr. 27, 2022
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr. 21, 2022
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr. 20, 2022
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr. 19, 2022
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr. 06, 2022
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr. 04, 2022
Todos Medical Reports Case Study of Patient with Long COVID
Mar. 31, 2022
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar. 28, 2022
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar. 16, 2022
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Mar. 08, 2022
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan. 27, 2022
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan. 24, 2022
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan. 19, 2022
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan. 18, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan. 12, 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan. 10, 2022
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec. 27, 2021
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec. 23, 2021
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec. 22, 2021
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec. 20, 2021
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec. 17, 2021
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec. 16, 2021
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec. 13, 2021
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec. 10, 2021
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec. 07, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
Dec. 07, 2021
Todos Medical to Present at Upcoming Emerging Growth Conference
Dec. 06, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec. 02, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov. 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov. 29, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov. 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov. 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov. 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov. 17, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov. 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov. 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov. 02, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Nov. 01, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
Oct. 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Oct. 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Oct. 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Oct. 06, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Oct. 04, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Sep. 30, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Sep. 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results
Fri, Sep. 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Sep. 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Sep. 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep. 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 15, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Sep. 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug. 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug. 24, 2021
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug. 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug. 23, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Aug. 02, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul. 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul. 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul. 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jul. 07, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
May 04, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr. 19, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr. 08, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Apr. 01, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar. 30, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar. 29, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar. 23, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Mar. 12, 2021
Todos Medical Applauds Senate and House Passage of the American Recovery Act
Mar. 11, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan. 25, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Jan. 11, 2021
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec. 23, 2020
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Dec. 14, 2020
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
Dec. 07, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec. 02, 2020
Todos Medical Provides Strategic Outlook
Dec. 01, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov. 24, 2020
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Nov. 20, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov. 18, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov. 17, 2020
Todos Medical Announces $867,000 in Sales for October 2020
Nov. 12, 2020
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
Oct. 29, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct. 26, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct. 22, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct. 20, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct. 13, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Oct. 07, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep. 30, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep. 25, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep. 22, 2020
Todos Medical CEO Releases Letter to Shareholders
Sep. 18, 2020
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Sep. 17, 2020
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
Sep. 16, 2020
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
Sep. 11, 2020
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
Sep. 03, 2020
Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing
Sep. 02, 2020
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Aug. 31, 2020
Todos Medical to Present at The LD 500 Virtual Conference
Aug. 31, 2020
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 27, 2020
Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations
Aug. 25, 2020
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
Aug. 24, 2020
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 21, 2020
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Aug. 17, 2020
Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test
Aug. 14, 2020
Todos Medical Announces July Sales of COVID-19 Tests
Aug. 07, 2020
Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug. 06, 2020
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Aug. 04, 2020
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
Aug. 03, 2020
Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Jul. 28, 2020
Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory
Jul. 27, 2020
Todos Medical Expands Management Team and Advisory Board
Jul. 20, 2020
Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Jul. 16, 2020
Todos Medical Releases Letter to Shareholders
Feb 07, 2020 9:15am EST
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
Jan 09, 2020 8:00am EST
Todos To Present At Upcoming 12th Annual LD Micro Main Event
Dec 06, 2019 7:29am EST
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
Nov 14, 2019 11:02am EST
Todos Medical to Present at Dawson James Small Cap Growth Conference
Oct 24, 2019 9:25am EDT
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
Sep 24, 2019 9:14am EDT
Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
Sep 13, 2019 7:30am EDT
Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan
Sep 03, 2019 1:29pm EDT
Todos Medical Appoints Dr. Jorge Leon as Medical Advisor
Aug 06, 2019 7:00am EDT
Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis
Jul 15, 2019 7:00am EDT
Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference
Jun 17, 2019 8:30am EDT
Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts
Jun 03, 2019 8:00am EDT
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
May 28, 2019 8:57am EDT
Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel
May 23, 2019 8:00am EDT
Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel
May 21, 2019 8:00am EDT
Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting
May 03, 2019 8:52am EDT
Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA)
May 01, 2019 8:00am EDT
Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries
Apr 15, 2019 8:00am EDT
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
Apr 08, 2019 7:30am EDT
Todos Medical to Present at Two Upcoming Investor Conferences
Mar 28, 2019 8:00am EDT
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
Mar 27, 2019 8:00am EDT
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
Feb 28, 2019 9:30am EST
Todos Medical Presents Encouraging Scientific Abstract at the San Antonio Breast Cancer Symposium (SABCS)
Dec 06, 2018 4:00pm EST
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
Dec 03, 2018 8:30am EST
Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)
Nov 29, 2018 8:30am EST
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
Oct 17, 2018 8:30am EDT
Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria
Sep 13, 2018 8:30am EDT
Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer
Jul 31, 2018 4:03pm EDT
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
Mar 22, 2018 8:00am EDT
Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening
Mar 05, 2018 8:00am EST
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
Feb 12, 2018 8:00am EST
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
Feb 06, 2018 8:00am EST
Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs
Aug 29, 2017 8:30am EDT
_____________________________________________________________________________________________
I'd say all my posts hold merit & truth...
as opposed to countless that led TOMDF into dissolvement proceedings - wouldn't you...?
no worries though - I'm sure the TOMDF Boiler Room Pumper Boys will keep you hooked
on buying more worthless shares of this TOMDF shit before the doors are permanently close & lights turned out...!
but hey, here's to your good fortunes in your TOMDF investment sir:
you were warned countless times - you deserve what you got sport...!
and what you got is the fact that you will NEVER get your $$$ back on the scam EVER
sorry - sad but true palzee...!
MOO pathetic
umh, fact check - here you go sir
brought up to you - just like room service:
thank God Nathan Hall's "orchestrated Peru deal" didn't go through
as a corroborating, extensive, and expensive survey conducted by FO from north to south Peru...
revealed horrendous gold revenue results at the mines in consideration - and as presented by WOGI
...and the many difficulties & challenges with mining in Peru in general
something that the clueless - such as yourself - don't know...!
unlike you - I stand behind all my posts - old - new - or otherwise...!
whoot whoot...!
BAF MONI
too funny and simply clueless...!
this 4-day 8K NASDAQ requirement "after legal approval" all started with CoachBarry ...
and went straight down hill from there - just who is this questionable 'Coach' character - lolzzz ?
also the 8k filing being 'stale' vs. OTC non-compliance are 2 different things altogether
in order to make a wonderful omelette - you need to crack few cracked eggs - sad but true...!
amazing how the blind lead the blind around here...
MONI will surprise...!
BAF MONI
MOO
here Rokky57 let me help add in a few things
TOMDF 3.3-Bil. OS in toxic death spiral convertible shares
and the printing of $0.0001 pps per catastrophic management, failed 'Business Planning 101' and scamming investors
here are 2 of those results - live and in living color for your starving truth-filled eyes:
https://investor.todosmedical.com/news-events/press-releases/detail/254/todos-medical-announces-insolvency-proceedings-in-israel
surprised to see your warm reception to JFB
especially when I laid out the results of JFB and the TOMDF Boiler Room Pumper Boys efforts ...
to pump this scam to the heavens and financially hurt individual investors
all the while, I tried to point out the obvious truth - to help protect you and others
and how they hide behind fake aliases, use fake IP addresses, use burner phones & work "in concert" with one another
but here, good fortunes to you surviving imminent insolvency and liquidation proceedings of TOMDF
Gerald is most likely heading into the 'wild blue yonder' early retirement - you know - with his AMBS and TOMDF winnings
and/or unemployed with a ginormous failed reputation to tote around on his resume
thanks in large part to JFB & Redspeed (ring leader) noob & gullible AMBS & TOMDF investors and their Boiler Room coharts
if this isn't enough to bring reality to your front door step - I don't know what else would ...
other than a balance of $0.00 in your TOMDF trade account...!
SMH - can't make this stuff up
MOO heinous
premarket - don't count on those numbers
here's a little diddy for your MONI "fact check" collection - lolzzz
and why I believe MONI has a whoop-ass punch or 2 left in its arsenal to become a success:
1. crystal clean SS
2. no debt on books
3. little to no dilution
4. current OTC Pink listing
5. timely security filings
6. small OH, GnA & OE's
7. reduced 2-Bil. shares w/no cost to SH’s
8. low consistent float moves on thin air
9. BitGift asset developed & on the books
10. BitGift trademark enforce
11. unencumbered by “dead weight” liabilities
12. huge untapped value in current Holdings Corporation structuring
13. in final negotiations to acquire target as a wholly owned sub thru non-dilutive measures
14. new acquisition target generating strong revenue’s
15. new acquisition target with “audited” financials
16. real possibility of further share reductions by new RM target
17. real probability of uplisting by new acquisition target
18. potential new CUSIP and elimination of ghost certificates
good fortunes to you "IF" you hold MONI
if not, then hasta leugo...!
BAF MONI
5 star post
couldn't agreed more - FO will move on and return to better health, family, friends and retirement
as a result of this acquisition consummation, I believe this security will be in much better, brighter and capable hands
MONI...
JFB always was and continues tobe full of shite
just like the rest of the TOMDF Boiler Room Pump Boys...!
and to think unsuspecting investors were gleefully following him and the other TOMDF Boiler Room Pump boys
and the CEO fake twitter Dr. and CEO hack
thinking this 3.3-Bil OS toxic death spiral POS was going to miraculously turn around somehow
SMH - what a bunch of organized scam artists
including the biggest POS twice failed CEO and Stanford University "Financial Engineer" hack
this guy has absolutely no morals or ethics whatsoever
IMHO, he sold his soul to the devil himself long ago - all for the love of greed, ego and money
MOO fraudster
the TOMDF Boiler Room Pumper Boi's knew all along this was a scam
we all know who they are - Redspeed, JoeyForkeyBolo aka Warp, Mauibound, GreaseMonkey, Gman111, etc etc etc
they continually pumped TOMDF and distorted reality on each news release, media interview, tweet, filing, public lecture, etc.
they even knew during the AMBS scam that AMBS was a scam....
but they did the exact same thing over there as they did here...
and they were going to sue me - for what exactly - that turned out tobe another fake hit job
they were also going to contact my employer and claim that I was bias and a racist
formal inquiry's in for list of complaints - absolute fools they are - not knowing they loaded the gun to their own heads
they discredit me and my family on multiple public forums
they ordered pizza and have it delivered to my house over and over again
they pumped and entice novice and "noob" investors with false narratives and claims of financial riches to be made
disgusting seedy underhanded scumbags that will rot in hell
they will not be eternally tormented for their sins, but by their sins...
they're little games are far from over - even with TOMDF's inevitable insolvency & liquidation imminent
MOO (my opinion only)
nice - tkx for sharing
looking for new acquisition target(s) audited fin's
also execute a SS reduction and/or uplisting efforts
maybe new CUSIP and shares - for starters...
congrats Frank, tkx for keeping MONI non-diluted, up-to-date filings, and financing MONI all these years
enjoy family, friends, and great health moving forward...!
$MONI
oh yeah, what's the volume...?
OEM
expecting OTC update w/ 8K anytime...!
$MONI
uhm - lets see now...
Todos Medical has had all of 2020, 2021, 2022 and 2023 - that's precisely 4 years to get Dr. Droit Arad on national TV
in order to tell her story - you know - like this one - that you've suggested:
umh - Dr Droit Arad and Todos Medical may no longer exist soon
Todos Medical is in current dissolvement proceedings
Tollovid is no longer available on Amazon - production has ceased
Todos has stopped paying bills and employees are no longer
an insolvency judge has taken over and is liquidating Todos Medical
denial is not a river in Egypt
false narratives will never be real - no matter how one wishes them to be so
projection is projection - sad but true
MOO reality
yeah good luck with that brah...!
Amazon dropped Tollovid:
https://www.amazon.com/s?k=tollovid+daily+3cl+protease+inhibitor&crid=1KRIQ9ACSSDSL&sprefix=tollovid+%2Caps%2C131&ref=nb_sb_ss_ts-doa-p_5_9
Todos is in dissolvement proceedings having blown (+/-) $138-Mil. in 5 yr's., and has ceased all Tollovid production
https://investor.todosmedical.com/news-events/press-releases/detail/254/todos-medical-announces-insolvency-proceedings-in-israel
anyone who has ordered Tollovid will have a hard time getting there money returned...
thanks Gerry - you suck as a CEO bro...!
SMH - sad but true
where did all that money go Gerald...???
investigate Gerald Commissiong...!
MOO insolvent
what is exceptionally odd and patently disturbing here is....
looking at a starter position for 2024
best wishes to all SH's
MONI closing in on major merger announcement anyday
1 yr. in the making has all the earmarks for something substantive
expecting this 1st merger to be 1 in a series of more to com
think audited financials, further SS reductions and uplisting
mo mo mo MONI...!
MOO